U.S. markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
97.19-2.48 (-2.49%)
At close: 4:00PM EST

97.17 -0.02 (-0.02%)
After hours: 7:54PM EST

Fate Therapeutics, Inc.

3535 General Atomics Court
Suite 200
San Diego, CA 92121
United States
858 875 1800
http://www.fatetherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees178

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Scott WolchkoFounder, CEO, Pres & Director850.5k1.73M1970
Dr. Daniel D. ShoemakerChief Scientific Officer525.94k806.74k1968
Ms. Cindy R. TahlGen. Counsel & Corp. Sec.525.94k1M1973
Dr. Bahram Valamehr Ph.D.Chief Devel. Officer525.94kN/A1977
Mr. Edward J. Dulac IIICFO & Principal Accounting OfficerN/AN/A1975
Dr. Wen Bo WangSr. VP of Technical OperationsN/AN/AN/A
Mr. Jim Beitel M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Dr. Sarah CooleySr. VP of Clinical TranslationN/AN/AN/A
Dr. Yu-Waye Chu M.D.Sr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Fate Therapeutics, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.